HT-29 Orthotopic Mouse Model Service for Colon Cancer

The HT-29 orthotopic mouse model offers a well-differentiated, microsatellite-stable human colorectal adenocarcinoma platform driven by BRAF V600E and PIK3CA co-mutations, enabling robust evaluation of BRAF-targeted agents, COX-2 inhibitors, and chemotherapeutic regimens within a physiologically authentic colonic microenvironment. Alfa Cytology constructs and manages this orthotopic xenograft system with authenticated HT-29 cell stocks, standardized cecal wall implantation protocols, and integrated histopathological and molecular endpoint analysis, delivering translationally relevant datasets that capture tumor differentiation status, stromal crosstalk, and therapeutic response in BRAF-mutant, MSS colorectal malignancies under in vivo conditions.

Overview of HT-29 Orthotopic Mouse Model for Colon Cancer

The HT-29 cell line is a human colorectal adenocarcinoma originally established in the late 1970s from the primary tumor of a 44-year-old Caucasian female patient diagnosed with grade II colorectal adenocarcinoma. Genetically, HT-29 is classified within the microsatellite-stable (MSS) molecular subtype, exhibiting a hyper-diploid karyotype with a high fraction of genome altered (FGA) characteristic of the chromosomal instability (CIN) pathway. The line harbors a pathogenic BRAF V600E activating mutation that drives constitutive MAPK/ERK signaling, alongside a concomitant PIK3CA missense mutation (P449T) that activates the PI3K/AKT/mTOR axis. Additional alterations include truncating mutations in APC (p.E853Ter, p.T1556NfsTer3), a missense mutation in TP53 (R273H), and a stop-gain mutation in SMAD4 (p.Q311Ter)—collectively rendering HT-29 a representative model for the BRAF-mutant, MSS subset of sporadic colorectal carcinoma that arises through the serrated neoplasia pathway. A distinctive biological feature of HT-29 is its retained capacity for differentiation: under appropriate conditions, cells can differentiate into goblet-like or absorptive phenotypes with mucin secretory competence, making this line uniquely valuable for studying intestinal epithelial differentiation alongside cancer biology.

Fig 1. Example of a failed injection of the HT-29 adenocarcinoma cells into the mucosa. (Cyr, Mélodie, et al., 2024)

Orthotopic implantation of HT-29 cells into the cecal wall of immunodeficient mice (athymic nude or NOD-scid strains) reconstructs the anatomical positioning, peritoneal environment, and stromal architecture of clinical colorectal cancer. Tumors establish reliably with high take rates and typically become palpable within 10–14 days post-implantation, progressing to endpoint volumes over 4–6 weeks. HT-29 exhibits high-level cyclooxygenase-2 (COX-2) expression, a feature linked to hematogenous metastasis potential and poor prognosis in clinical disease. The model has been extensively validated for evaluating BRAF inhibitors (e.g., vemurafenib), EGFR-directed therapies, COX-2 inhibitors (e.g., celecoxib), and standard chemotherapeutics including 5-fluorouracil and irinotecan. The combination of BRAF-mutant tumor biology, MSS molecular context, documented COX-2-driven biology, and differentiation plasticity renders this model particularly powerful for preclinical evaluation of targeted agents, anti-metastatic strategies, and multidrug resistance mechanisms in the most common molecular subtype of colorectal cancer seen in clinical practice.

Cell Line Information: HT-29

HT-29 is among the most extensively utilized human colorectal adenocarcinoma cell lines in preclinical oncology, distinguished by its BRAF V600E mutation, MSS molecular context, and unique differentiation plasticity. The table below consolidates its essential biological, genetic, and culture parameters:

Our Services

Alfa Cytology delivers a comprehensive HT-29 orthotopic model service encompassing authenticated cell line banking, surgical cecal wall implantation in immunodeficient hosts, longitudinal tumor monitoring, therapeutic intervention, and multi-layered endpoint analysis spanning histopathology, molecular profiling, and differentiation marker assessment. Our platform is optimized for BRAF-targeted therapy, COX-2 inhibitor, and chemotherapy resistance studies in MSS colorectal cancer, delivering robust, mechanism-informed datasets that advance your preclinical pipeline with scientific rigor.

Workflow of HT-29 Orthotopic Mouse Model Construction

Establishment of the HT-29 orthotopic model requires meticulous surgical technique, authenticated human cell line stocks, and immunodeficient host management to achieve consistent engraftment and physiologically relevant tumor growth. The protocol proceeds through the following sequential stages:

1. Cell Expansion and Authentication: HT-29 cells are propagated in RPMI 1640 with 10% FBS, harvested during logarithmic growth to maximize tumorigenic potential, and authenticated via STR profiling against the human reference. Mycoplasma negativity is confirmed by PCR. Cells are washed, counted by automated hemocytometer, and resuspended in ice-cold PBS at a concentration of 1 × 10⁷ cells/mL for in vitro preparation.
2. Recipient Mouse Preparation: Female athymic nude (BALB/c nu/nu) or NOD-scid mice (6–8 weeks old) are quarantined and acclimated for a minimum of 72 hours. Health status is assessed daily, and any mice displaying abnormal behavior or weight loss are excluded prior to cell implantation.
3. Matrigel Suspension Preparation: The cell suspension is mixed 1:1 by volume with ice-cold Matrigel Basement Membrane Matrix immediately prior to injection. Matrigel provides an extracellular scaffold that supports initial tumor colonization within the cecal wall, enhances engraftment consistency, and facilitates glandular differentiation and stromal interaction.
4. Surgical Cecal Wall Implantation: Under general anesthesia, a midline laparotomy (~10 mm) is performed, and the cecum is exteriorized onto sterile gauze moistened with PBS. A small cecotomy is made at the cecal tip, and 50–100 µL of the Matrigel-cell suspension (5 × 10⁵ to 1 × 10⁶ cells) is injected submucosally into the cecal wall from the luminal side using a 27-gauge needle. The cecotomy is closed with interrupted 5-0 silk sutures in Lembert fashion, the cecum is returned to the abdominal cavity, and the abdominal wall is closed in two layers.
5. Postoperative Care and Monitoring: Mice receive sustained-release buprenorphine for analgesia and are monitored closely during the 48-hour perioperative period for signs of pain, dehydration, or intestinal obstruction. Body weights are recorded daily for the first week and twice weekly thereafter.
6. Tumor Monitoring and Cohort Randomization: Tumor establishment is assessed by palpation of the abdominal cavity beginning on day 7–10 post-surgery. Once tumors reach 50–100 mm³, mice are randomized into treatment cohorts based on tumor volume to ensure balanced baseline distributions across all experimental arms.
7. Therapeutic Intervention and Longitudinal Assessment: Test compounds are administered according to the predefined regimen (dose, route, frequency, and duration). Tumor dimensions are measured twice weekly with digital calipers, and body weights are recorded concurrently to monitor treatment tolerability. Optional high-frequency ultrasound imaging can be incorporated for non-invasive volumetric assessment and glandular architecture visualization.
8. Endpoint Necropsy and Comprehensive Analysis: Upon reaching study endpoints (tumor volume ~2,000 mm³, humane moribund criteria, or scheduled termination), mice are euthanized. The primary cecal tumor is excised, weighed, and photographed. The liver, lungs, and mesenteric lymph nodes are harvested for metastasis assessment. Tumor tissues are fixed for H&E and immunohistochemistry (COX-2, CD31, Ki-67, cleaved caspase-3, phospho-ERK, MUC2, CEA), or snap-frozen for Western blot, qPCR, and RNA-seq.

Fig 2. HT-29 Orthotopic Mouse Model construction workflow.

Case Study-HT-29 Orthotopic Mouse Model Development

In a preclinical program investigating BRAF-mutant colorectal cancer therapy, the HT-29 orthotopic model was employed to evaluate the efficacy of a novel BRAF inhibitor administered as monotherapy and in combination with a MEK inhibitor and an EGFR-directed antibody. Following surgical cecal wall implantation and postoperative recovery, tumor-bearing mice were randomized into treatment arms receiving the BRAF inhibitor alone, the MEK inhibitor alone, the EGFR antibody alone, dual combinations, the triple combination regimen, or vehicle control. Longitudinal tumor monitoring revealed that the BRAF inhibitor monotherapy produced only modest growth inhibition, consistent with documented feedback reactivation of EGFR signaling in BRAF-mutant colorectal cancer. In contrast, the triple combination cohort exhibited profound and sustained tumor growth suppression throughout the study duration, with significantly reduced tumor volume compared to all other arms. Endpoint histopathological analysis demonstrated markedly reduced phospho-ERK staining, diminished COX-2 expression, and increased cleaved caspase-3 in the triple combination-treated tumors, alongside preserved glandular differentiation architecture. These findings illustrate the model's utility in dissecting BRAF inhibitor resistance mechanisms, validating combination strategies that overcome feedback signaling, and informing clinical trial design for BRAF-mutant MSS colorectal malignancies.

Why Choose Alfa Cytology?

Selecting Alfa Cytology for your HT-29 orthotopic colon cancer study ensures access to a scientifically rigorous, quality-focused CRO platform with deep expertise in human xenograft model construction and BRAF-targeted therapy evaluation. Our core differentiators include:

• Authenticated HT-29 cell banking with documented STR profiling, mycoplasma clearance, and low-passage expansion to preserve BRAF V600E/PIK3CA mutation fidelity, differentiation capacity, and COX-2 expression levels across study cohorts.
• Skilled surgical team experienced in cecal wall orthotopic implantation with high take rates and low perioperative mortality, ensuring robust statistical power and reproducible tumor growth kinetics in immunodeficient hosts.
• Integrated histopathology and molecular profiling capabilities featuring validated antibody panels for BRAF V600E, phospho-ERK, phospho-AKT, COX-2, Ki-67, cleaved caspase-3, MUC2, CEA, and CD31 vascular markers.
• Differentiation status assessment via mucin staining (Alcian Blue, PAS) and goblet cell marker profiling, enabling evaluation of therapeutic effects on tumor differentiation plasticity alongside proliferation and apoptosis endpoints.
• Flexible combination study designs supporting BRAF inhibitors, MEK inhibitors, EGFR-directed therapies, COX-2 inhibitors, and standard chemotherapeutics with customized dosing schedules, sequential treatment arms, and resistance monitoring.
• Dedicated project scientists providing weekly progress updates, interim data reviews, and collaborative interpretation of pharmacodynamic and efficacy endpoints to align preclinical outcomes with your clinical development strategy for BRAF-mutant MSS colorectal cancer.

Contact Us

If your preclinical pipeline demands a BRAF-mutant, MSS colorectal cancer model that faithfully recapitulates the in vivo tumor microenvironment of the most prevalent clinical molecular subtype, we invite you to reach out to us to discuss how Alfa Cytology can design and execute a tailored HT-29 orthotopic study aligned with your therapeutic hypotheses. From surgical implantation and BRAF-targeted therapy dosing through differentiation status assessment and comprehensive endpoint profiling, our team is committed to delivering translationally relevant data that advance your colorectal cancer drug development program. Contact us today to initiate your project and leverage our specialized expertise in BRAF-mutant MSS colorectal cancer preclinical research.

For research use only. Not intended for any clinical use.